PPT-Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors

Author : yoshiko-marsland | Published Date : 2019-12-11

Type 1 Diabetes Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors IntroductionOverview Intensive Therapy Reduces Diabetes Complications Rates Variability

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Type 1 Diabetes: Expanding Options for A..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors: Transcript

Type 1 Diabetes Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors IntroductionOverview Intensive Therapy Reduces Diabetes Complications Rates Variability in TimeAction Profile of Basal Insulins. Weirui. Chai. 4/12/2011. Content. Diabetes – High Blood . Sugar. Type 1 and Type 2 . Diabetes. Treatments for Type 2 . Diabetes. Conclusion. Diabetes – High Blood Sugar. Diabetes . mellitus:. A . Roland Halil, . BScPharm, ACPR, PharmD. Clinical Pharmacist, Bruyere Academic Family Health Team. Assistant Professor, Dept of Family Medicine, U of Ottawa. July 2016. Objectives. List the classes of oral antihyperglycemic agents and understand their place in therapy.. Diabetes Mellitus: Overview of the Disease and Its Treatment. Diabetes mellitus . Greek word for “fountain”. Latin word for “honey”. Disorder of carbohydrate metabolism. Deficiency of insulin. Program Goals. The . Incretin System: Response to Oral Glucose. Injected Incretin-based Agents: GLP-1 Receptor Agonists. Oral Incretin-based Agents: DPP-4 Inhibitors . Main Pathophysiological Defects in T2D. SGLT Inhibitors. Program Overview. Glycemic Control in T1DM. Risks Associated With T1DM. Limitations of Insulin Therapy for T1DM. Noninsulin Therapy for T1DM: Pramlintide. T2DM Therapies for T1DM: Metformin. A Look Back on Diabetes in 2015 to Look Forward in 2016 Alan B Cortez, MD May 14, 2016 Pediatric Endocrinology Kaiser Permanente Orange County Categories of Review rather than Preview (Research) Education Oral hypoglycemics. Factors to consider:. Cost. Availability. Side effects. Tolerability. Risk. Accessory benefits. metformin. Metformin is the . preferred initial pharmacologic agent . for the treatment of type 2 diabetes. . Dr. . . Ghadiri. , MD. Assistance professor of endocrinology. Shahid. . Sadoughi. . University of Medical Sciences . 2. The importance of glycemic control in minimizing complications related to diabetes has been well established in type 1 diabetes . By:. . Akash Saxena. KLE . College of Pharmacy, . Belagavi. A constituent Unit of KLE Academy of Higher Education and Research. Nehru Nagar, . Belagavi. . –. 590 010, Karnataka, India. Phone:. 0831-2471399;. What Follows Metformin? . James R. Gavin III, MD, PhD. CEO & Chief Medical Officer, Healing Our Village, Inc.. Clinical Professor of Medicine. Emory University, School of Medicine. Atlanta, Georgia USA. Intensive Insulin Management 10Basal: Once-daily, either morning or bedtime(alternative: NPH morning and bedtime)Bolus: Fast-acting insulin before each meal;(alternative: R may be used)Premeal insulin . Diabetes action Canada annual workshop. Friday, MAY 31, 2019 . Bruce A. Perkins, Leif E. Lovblom, Nancy Cardinez, Andrej . Orszag,. Marcelo . Falappa, Devrim Eldelekli, Daniel Scarr, Ahmad Haidar. Disease . By . . Jean . Molinary. , . DO. Screening for Diabetes . in . Adults. ADA: Risk based, or starting at the age of 45, then every . 3 years . if normal. Diabetes is Target-oriented. :. Macrovascular complications: higher with DM. S.Kalbasi. , . MD. Associated . professor of Internal Medicine, Endocrinology and Metabolism . Shahid. . Beheshti. University of Medical Sciences Research Institute for Endocrine . Scences. 1/18/2018.

Download Document

Here is the link to download the presentation.
"Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.